Including Toxicity Risk in Balanced Clinical Decision Making

  • Jean L. WrightEmail author


Adjuvant radiation therapy has been an established component of curative therapy for early-stage and locally advanced breast cancer for decades, and over this time frame, outcomes have steadily improved, including survival. Longer survival has in turn shifted the focus in breast cancer therapy toward preventing, minimizing, and managing the toxicities of treatment. Clinical decision-making has always relied on a balanced assessment of the benefit of therapy versus the risks and side effects of treatment. This balance has become all the more challenging in the modern era of excellent outcomes for breast cancer patients. In light of this increased recognition of the importance of toxicity from breast cancer therapy in clinical decision-making, this textbook serves as a comprehensive review of the common toxicities associated with radiation for breast cancer. The goal of this book is to facilitate the individualized assessment of toxicity risk and make recommendations for toxicity management to better tailor and optimize treatment for our breast cancer patients.


Breast cancer Radiation therapy Toxicity Side effects Clinical decision-making 


  1. 1.
    Early Breast Cancer Trialists’ Collaborative G, Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.CrossRefGoogle Scholar
  2. 2.
    Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.CrossRefGoogle Scholar
  3. 3.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.CrossRefGoogle Scholar
  4. 4.
    Whelan TJ, Olivotto IA, Levine MN. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(19):1878–9.Google Scholar
  5. 5.
    Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, et al. Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology focused guideline update. Pract Radiat Oncol. 2016;6(6):e219–e34.CrossRefGoogle Scholar
  6. 6.
    Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382–7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Johns Hopkins University, Department of Radiation Oncology and Molecular Radiation SciencesBaltimoreUSA

Personalised recommendations